| Date | Player/Plan | Drug/ Device | Change |
|-----------------------|-------------------------|--------------------------|--|
| | | | INCRETIN MIMETICS (GLP-1 RAS/GIP) Commercial |
| 4/25/25 | Priority (Optimized) | Trulicity, Mounjaro | Added to PA criteria (iin bold): T2D diagnosis AND Therapeutic failure after 3 month trial at max dose for at least 2 generic oral anti-diabetic agents AND in conjunction with diet and exercise, and not achieving adequate glycemic control (must be within the last SIX months) |
| 1/2/25 | All Plans | liraglutide (generic) | Added liraglutide (generic) - FDA approved as of 12/23/2024. |
| 1/1/25 | All Plans | Victoza | Was Preferred Brand, Now: Non-Formulary. FDA approved generic liraglutide on 12/23/24. |
| Effective 1/1/2025 | Express Scripts | GLP-1 RA | Prior authorization criteria updated as of 9/18/24 michmed.org/3xAey: |
| | | | Adlyxin, Byetta, Mounjaro, Ozempic, Rybelsus: If criteria for previous use of an oral medication for diabetes (not including Rybelsus or single-entity metformin) in the past 130 days are not met at the point of service, OR if the patient is < 18 years of age, coverage will be determined by Prior Authorization criteria. |
| | | | Bydureon BCise, Trulicity, Victoza, liraglutide (authorized generic to Victoza): If criteria for previous use of an oral medication for diabetes (not including Rybelsus or single-entity metformin) in the past 130 days are not met at the point of service, OR if the patient is < 10 years of age, coverage will be determined by Prior Authorization criteria. |
| | | | Recommended Authorization Criteria Coverage is recommended in those who meet the following criteria: |
| | | | FDA-Approved IndicationType 2 Diabetes Mellitus |
| | | | Approve for 1 year if the patient meets ONE of the following (A or B): If the request is for Adlyxin, Byetta, Mounjaro, Ozempic, Rybelsus: Approve if the patient is ≥ 18 years of age; OR If the request is for Bydureon BCise, Trulicity, Victoza, liraglutide (authorized generic to Victoza): Approve if the patient is ≥ 10 years of age. |
| 1/1/25 | HAP Commercial | liraglutide (generic) | Was Non-Preferred, Now Preferred Generic with PA and step therapy |
| 1/1/25 | Priority Optimized | Mounjaro, Trulicity | Prior authorization criteria no longer requires A1C between 7% and 9% |
| | | | INCRETIN MIMETICS Medicare Advantage |
| 01/01/ 2025 | Aetna MA | liraglutide | Was "Unknown." Now Tier 4 - Non-Preferred. |
| 01/01/ 2025 | BCBSM/BCN MA | GLP-1RA | Bypass PA: ICD-10 (T2D DX) on pharmacy profile from med claim or T2D Rx claim within the past year |

| Date | Player/Plan | Drug/ Device | Change |
|----------------|----------------------|----------------------|---|
| 01/01/ 2025 | НАР МА | liraglutide | Was "Unknown." Now Generic - Tier 2 |
| 01/01/ 2025 | НАР МА | Ozempic, Rybelsus | Was "Preferred Brand." Now Not Covered |
| 01/01/2 025 | Humana MA | Victoza | Was "Preferred Brand" now "Not Covered" |
| 01/01/2 025 | Priority MA | Victoza | Was "Non-Preferred: PA Trial of Trulicity." Now "Not Covered" |
| | | | INCRETIN MIMETICS - Medicaid |
| 01/01/2 025 | Molina Medicaid | All | Added: Molina Medicaid: PA criteria michmed.org/JDqXY T2D DX Documented 3 month trial & failure with metformin Documented of individualized goals for therapy AND Provider attestation: No FDA contraindications for use |
| | | | SGLT2i |
| 01/01/ 2025 | Michigan Medicaid | Brenzavvy | Was "Unknown." Now Non-Preferred with PA |
| 01/01/ 2025 | Michigan Medicaid | Invokana | Was "Preferred Brand." Now Non-Preferred |
| | | | Anti-Obesity Medications |
| 1/1/25 | BCBSM Comercial | Wegovy, Saxenda | No longer covered. Provider Bulletin https:// providerinfo.bcbsm.com/documents/alerts/2024/202406/ alert-20240606-changes-weight-loss-drugs-commercial.pdf |
| 1/1/25 | Michigan Medicaid | All | Change disclaimers from Magellan (PBM) to Prime Therapeutics (PBM) with updated links to PA criteria |

| Date | Player/Plan | Drug/ Device | Change |
|----------------|----------------------------|-----------------|--|
| | | | ССВМ |
| 4/25/25 | All Plans | CGM | Abbott is discontinuing its Libre 2 and Libre 3 models, available until 09/30/2025. Prescribers can transition to the Libre 2 Plus or Libre 3 Plus models to avoid gaps in care. More info: https://www.freestyle.abbott/us-en/transition.html |
| 4/25/25 | United (Commerci al) | CGM | FIXED error in criteria, adding hypoglycemic event option: "THREE (3) times daily insulin OR Level 2 or Level 3 hypoglycemic events" UHC Policy updated 7/2024. ADDED Pharmacy option for CGM, in addition to DME. Either can be used, no preferred copay. |
| 01/01/2 025 | United | ССМ | Adapt Health DME supplier phone number change |

COVERAGE GUIDE GLP-1 RA / GIP for COMMERCIAL

Find a glossary of ICD10 codes on last page.

| COMMERCIAL PLAN Formulary Link | MOUNJARO Tirzepatide Injectable - Weekly | TRULICITY Dulaglutide Injectable - Weekly | OZEMPIC Semaglutide (SQ) Injectable - Weekly | RYBELSUS Semaglutide Oral - Daily | VICTOZA Liraglutide Injectable - Daily | LIRAGLUTIDE (generic) Injectable - Daily | |
|--|--|--|---|---|--|---|---|
| AETNA michmed.org/97 Ay9 | Preferred Bypass PA: ICD10 in RX or metformin claim | Preferred Bypass PA: ICD10 in RX or metformin claim | Preferred Bypass PA: ICD10 in RX or metformin claim | Preferred Bypass PA: ICD10 in RX or metformin claim | Non Formulary | Generic PA | |
| BCBSM/BCN michmed.org/ nmxVD | Preferred ¹ Bypass PA (see note on right) | Preferred¹ Bypass PA (see note on right) | Preferred ¹ Bypass PA (see note on right) | Preferred ¹ Bypass PA (see note on right) | Non Preferred/ Not Covered ² | Generic ¹ Bypass PA (see note on right) | [1] BCBSM: Bypass PA: ICD-10 (T2D DX) on pharmacy |
| EXPRESS SCRIPTS michmed.org/ Dyq2x | Preferred Bypass PA: T2D DX | Preferred Bypass PA: T2D DX | Preferred Bypass PA: T2D DX | Preferred Bypass PA: T2D DX | Not Covered | Unknown | profile from med claim or T2D Rx claim within the past year [2] BCBSM: Brand |
| HAP michmed.org/ qdV9P | Preferred Brand ST: 90-day trial/ failure metformin within last 120 days | Preferred Brand ST: 90-day trial/ failure metformin within last 120 days | Preferred Brand ST: 90-day trial/ failure etformin within last 120 days | Preferred Brand ST: 90-day trial/failure metformin within last 120 days | Non Formulary | Generic PA ST | Victoza is Non- Preferred for patients with the Custom and Clinical Formulary and Not Covered for patients with |
| PRIORITY ³ michmed.org/ yq299 | Preferred Bypass PA: ICD10 on file | Preferred Bypass PA: ICD10 on file | Non Formulary ^{Tier 9} | Non Formulary _{Tier 9} | Non Formulary Tier 9 | Not Covered | the Custom Select, Preferred Drug list, or closed formulary design. |
| PRIORITY OPTIMIZED michmed.org/ BA4Kb | Preferred PA ⁴ | Preferred PA ⁴ | Not Covered Tier 9 | Not Covered Tier 9 | Not Covered Tier 9 | Not Covered | |
| UNITED michmed.org/7N JrY | Preferred PA ICD10 in RX or labs if DX < 2 years | Preferred PA ICD10 in RX or labs if DX < 2 years | Preferred PA ICD10 in RX or labs if DX < 2 years | Preferred PA ICD10 in RX or labs if DX < 2 years | Not Covered | Preferred PA ICD10 in RX or labs if DX < 2 years | |

[3] For Priority Health employer group and individual HSA plans with chronic condition rider: Trulicity/Mounjaro have been removed from 2025 Chronic Condition Drug rider list. Affected patients will be paying towards their deductible with these claims now. For example: A patient with a \$4000 deductible, Tier 2 copay of \$40/month, and out of pocket maximum (OOP) of \$8000. In 2024, the patient paid \$40/month on Trulicity until their OOP limit was met. In 2025, the patient would pay ~\$1000/month on Trulicity until their \$4000 deductible is met, then will pay \$40/month until their \$8000 OOP is met.

- [4] Priority Optimized PA for Mounjaro/Trulicity:

 T2D diagnosis AND Therapeutic failure after 3 month trial at max dose for at least 2 generic oral anti-diabetic agents AND in conjunction with diet and exercise, and not achieving adequate glycemic control (must be within the last SIX months)
- Documentation should include specific actions, e.g. Patient uses app to track calories and is no longer snacking at night. Patient is walking 30 minutes 3x week. Documentation should be consistent - no discrepancies in past 1-2 months of notes.

[1] BCBSM/BCN

Generic liraglutide is Tier 1 (Generic) for UAW Trust

MA:

Group.



COVERAGE GUIDE GLP-1 RA / GIP for MEDICARE ADVANTAGE

| MEDICARE PLAN Formulary Link | MOUNJARO Tirzepatide Injectable - Weekly | TRULICITY Dulaglutide Injectable - Weekly | OZEMPIC Semaglutide Injectable - Weekly | RYBELSUS Semaglutide Oral - Daily | VICTOZA Liraglutide Injectable - Daily | LIRAGLUTIDE (generic) Injectable - Daily |
|--|--|--|--|--|---|--|
| AETNA MA michmed.org/8N Qrk | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Non- Preferred | Non- Preferred |
| BCBSM/BCN MA michmed.org/ DymRY | Preferred Brand Bypass PA: ICD10 in med claim for pt visit | Preferred Brand Bypass PA: ICD10 in med claim for pt visit | Preferred Brand Bypass PA: ICD10 in med claim for pt visit | Preferred Brand Bypass PA: ICD10 in med claim for pt visit | Non Formulary | Non Formulary¹ |
| HAP MA michmed.org/8N Qrk | Preferred Brand ST: Metformin within last 120 days | Preferred Brand ST: 90-day trial/ failure metformin within last 120 days | Not Covered | Not Covered | Not Covered | Generic Tier 2 |
| HUMANA MA michmed.org/ kQ894 | Preferred Brand | Preferred Brand | Preferred Brand | Preferred Brand | Not Covered | Non- Preferred Tier 4 |
| PRIORITY MA michmed.org/7N VGN | Preferred Brand ICD 10 in RX PA | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Not Covered | Unknown |
| UNITED MA AARP Preferred michmed.org/ YkDR3 | Preferred Brand PA | Preferred Brand PA | Preferred Brand PA | Preferred Brand PA | Not Covered | Unknown |
| WELLCARE MA¹ michmed.org/ gRWDV | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Preferred Brand ICD10 in RX PA | Non- Preferred | Non- Formulary |

^[1] Note on Wellcare MA: "Tier 6: Select Care Drugs" denotes certain brand-name medications that treat type 2 diabetes with relatively low copays



GLP-1 RA / GIP AND SGLT2i for MEDICAID

| MEDICAID PLAN Formulary Link | MOUNJARO Tirzepatide Injectable - Weekly | TRULICITY Dulaglutide Injectable - Weekly | OZEMPIC Semaglutide (SQ) Injectable - Weekly | RYBELSUS Semaglutide Oral - Daily | VICTOZA Liraglutide Injectable - Daily | LIRAGLUTIDE (generic) Injectable - Daily |
|---|--|---|---|---|---|---|
| MICHIGAN MEDICAID michmed.org/ N2wn8 | Non- Preferred PA ³ | Preferred Brand PA ^{1, 2} ICD10 in RX or T2D med | Preferred Brand PA ^{1, 2} ICD10 in RX or T2D med | Non- Preferred PA ³ | Preferred Brand PA ^{1, 2} ICD10 in RX or T2D med | Non- Preferred <mark>PA</mark> ³ |

Find a glossary of ICD10 codes on last page

| MEDICAID PLAN Formulary Link | JARDIANCE Empagliflozin Oral - Daily | FARXIGA Dapagliflozin Oral - Daily | INVOKANA Canagliflozin Oral - Daily | STEGLATRO Ertugliflozin Oral - Daily | BRENZAVVY Bexagliflozin Oral - Daily |
|---|---|---|--|--|--|
| MICHIGAN MEDICAID michmed.org/ N2wn8 | Preferred Brand | Preferred Brand | Non- Preferred PA ⁴ | Non-Preferred PA ⁴ | Not Covered PA ⁴ |

[1] Michigan
Medicaid: For most
up-to-date PA
criteria, see:
michmed.org/2VP94
and click on "Drug
PA criteria' link.

[2] Molina Medicaid: PA criteria michmed.org/JDqXY

- T2D DX
- Documented 3 month trial & failure with metformin
- Documented of individualized goals for therapy AND
- Provider attestation: No FDA contraindications for use

- [3] As of Feb 1, 2025, **Non-Preferred GLP-1 RAs** (Bydureon Bcise, exenatide, liraglutide, Mounjaro, Rybelsus) must meet the following PA criteria. Duration of approval: Up to 1 year.
- 1. Diagnosis of type 2 diabetes
- 2. Discontinuation of other GLP-1 agonists
- 3. And one of the following:
 - a. Allergy to the preferred medications, OR
 - b. Contraindication or drug to drug interaction with the preferred medications; OR
 - c. History of unacceptable side effects; OR
 - d. Trial and failure with one preferred medication within same subgroup.

As of Feb 1, 2025, **Non-Preferred SGLTi's** (dapagliflozin, Inpefa, Steglatro) must meet the following PA criteria. Duration of approval: Up to 1 year.

- 1. Allergy to the preferred medications, OR
- 2. Contraindication or drug to drug interaction with the preferred medications; OR
- 3. History of unacceptable side effects; OR
- 4. Trial and failure with one preferred medication within same class .

SGLT2i for COMMERCIAL

| COMMERCIAL PLAN Formulary Link | JARDIANCE Empagliflozin Oral - Daily | FARXIGA Dapagliflozin ¹ Oral - Daily | INVOKANA Canagliflozin Oral - Daily | STEGLATRO Ertugliflozin Oral - Daily | BRENZAVVY Bexagliflozin Oral - Daily |
|--|---|--|---|--|--|
| AETNA michmed.org/97 <u>Ay9</u> | Preferred Brand | Preferred Brand | Not Covered | Not Covered | Unknown |
| BCBSM michmed.org/ nmxVD | Preferred Brand | Preferred Brand | Not Covered | Not Covered | Not Covered |
| EXPRESS SCRIPTS michmed.org/ Dyq2x | Preferred | Preferred | Not Covered | Preferred | Unknown |
| HAP michmed.org/ qdV9P | Preferred Brand | Preferred Brand | Non Formulary | Non Formulary | Unknown |
| PRIORITY michmed.org/ yq299 | Preferred Brand | Preferred Brand | Non- Preferred ST* | Non-Preferred ST* | Not Covered |
| PRIORITY OPTIMIZED michmed.org/ BA4Kb | Preferred Brand | Preferred Brand | Non- Preferred ST* | Non-Preferred ST* | Not Covered |
| UNITED michmed.org/7N JrY | Preferred Brand | Non Formulary ST/PA** | Non Formulary ST/PA** | Non Formulary ST/PA** | Non Formulary ST/PA** |

¹Authorized generic formulation of dapagliflozin (Farxiga) Not Covered

*Step therapy for Priority Must first try Jardiance, Farxiga, Xigduo, or Synjardy

**Step therapy/PA for United
History of suboptimal response
(after three month trial),
contraindication or intolerance to
metformin AND Jardiance

SGLT2i for MEDICARE ADVANTAGE

| MEDICARE PLAN Formulary Link | JARDIANCE Empagliflozin Oral - Daily | FARXIGA Dapagliflozin¹ Oral - Daily | INVOKANA Canagliflozin Oral - Daily | STEGLATRO Ertugliflozin Oral - Daily | BRENZAVVY Bexagliflozin Oral - Daily | [1] Authorized generic formulation of dapagliflozin (Farxiga) Not Covered |
|--|---|---|--|--|--|---|
| AETNA MA michmed.org/8N Qrk | Preferred Brand | Preferred Brand | Not Covered | Not Covered | Not Covered | |
| BCBSM/BCN MA michmed.org/ DymRY | Preferred Brand | Preferred Brand ² | Not Covered ³ | Not Covered | Non Formulary | [2] BCBSM/BCN MA: Farxiga is Non Formulary for UAW Trust Group. [3] BCBSM/BCN MA: |
| HAP MA michmed.org/8N Qrk | Preferred Brand | Preferred Brand | Non Formulary | Non Formulary | Not Covered | Invokana is Preferred (Tier 2) for UAW Trust Group. |
| HUMANA MA michmed.org/ kQ894 | Preferred Brand | Non- Preferred _{Tier 4} | Preferred Brand | Not Covered | Not Covered | |
| PRIORITY MA michmed.org/7N VGN | Preferred Brand | Preferred Brand | Non- Preferred ST* | Not Covered | Not Covered | * Step therapy for Priority Must first try Jardiance, Farxiga, Xigduo, or Synjardy |
| UNITED AARP michmed.org/ YkDR3 | Preferred Brand | Preferred Brand | Not Covered | Not Covered | Not Covered | |
| WELLCARE MA** michmed.org/ gRWDV | Select Care Tier 6 | Select Care Tier 6 | Non- Preferred _{Tier 4} | Not Covered | Not Covered | **Note on Wellcare MA: "Tier 6: Select Care Drugs" denotes certain brand-name medications that treat type 2 diabetes with relatively low copays |



ANTI-OBESITY MEDS for COMMERCIAL

| PLAN NAME Formulary Link | SAXENDA Liraglutide Injectable - Daily | WEGOVY Semaglutide Injectable - Weekly | ZEPBOUND Tirzepatide Injectable - Weekly | CONTRAVE Naltrexone HCl - Buproprion HC Oral - 2x Daily | LOMAIRA Phentermine 8mg Low Dose Oral - Daily w/Meals | PHENTERMINE Generic - High Dose Oral - Daily w/ Meals | QSYMIA Phentermiine - Topiramate Oral - Daily |
|---------------------------------------|--|---|---|--|---|---|--|
| AETNA michmed.org /97Ay9 | Preferred Brand PA ¹ | Preferred Brand PA ¹ | Non Formulary | Non Formulary | Not Covered | Preferred Generic PA | Preferred Generic PA |
| BCBSM* michmed.org /nmxVD | Not Covered ² | Not Covered ² | Not Covered ² | Non- Preferred Brand PA ³ | Non- Preferred Brand | Preferred Generic | Non- Preferred Brand PA ³ |
| EXPRESS SCRIPTS michmed.org /Dyq2x | Not Covered | Preferred PA | Preferred | Non- Preferred PA | Not Covered | Not Covered | Not Covered |
| HAP michmed.org /qdV9P | Non Formulary | Non Formulary | Non Formulary | Non Formulary | Non Formulary | Non Preferred Generic Tier 1A | Non- Preferred Brand PA |
| PRIORITY michmed.org/ yq299 | Not Covered ² | Not Covered ² | Not Covered ² | Non- Preferred ST: Try generic first | Non- Preferred ST: Try generic first | Preferred Generic | Non- Preferred ST: Try generic first |
| PRIORITY OPTIMIZED michmed.org/ BA4Kb | Not Covered ² | Not Covered ² | Not Covered ² | Non- Preferred ST: Try generic first | Not Covered | Preferred Generic | Non- Preferred ST: Try generic first |
| UNITED michmed.org /7NJrY | Not Covered ³ | Not Covered ³ | Not Covered ³ | Non- Preferred PA ³ | Non- Preferred PA ³ | Preferred Generic Tier 1 PA ³ | Non- Preferred PA ³ |

- 1. Aetna PA criteria for Wegovy: michmed.org/QRQMm
- 2. BCBSM: Saxenda, Wegovy, and Zepbound are Not Covered for fully insured. Coverage for Self-Funded groups may vary.
- 3. BCBSM PA criteria for Weight Loss Medications (see next page) or BCBSM document michmed.org/zRQZ
- 4. Prior authorization may be available for some employers. Patient should contact their HR Benefits Advisor to find out if their employer has an exception allowing these meds. PA criteria for AOM: michmed.org/GgeVY

ANTI-OBESITY MEDS for Medicare Advantage



Medicare Advantage plans do not cover anti-obesity medications at this time.

ANTI-OBESITY MEDS for Medicaid

| PLAN NAME Formulary Link | SAXENDA Liraglutide Injectable - Daily | WEGOVY Semaglutide Injectable - Weekly | ZEPBOUND Tirzepatide Injectable - Weekly | CONTRAVE Naltrexone HCI - Buproprion HC Oral - 2x Daily | LOMAIRA Phentermine 8 Low Dose Oral - Daily w/Meals | PHENTERMINE Generic - High Dose Oral - Daily w/ Meals | QSYMIA Phentermiine - Topiramate Oral - Daily |
|--------------------------------------|--|---|--|--|---|---|--|
| MICHIGAN MEDICAID michmed.org/ N2wn8 | Preferred PA | Preferred PA | Preferred PA | Not Covered | Preferred PA | Preferred PA | Not Covered |

Michigan Medicaid PDL Prime Therapeutics RX Prior Auth Criteria for Anti-Obesity Medications:

For most up-to-date criteria, see Michigan Medicaid page michmed.org/2VP94 and click on "Drug PA criteria' link (Last checked 2/1/2025) **INITIAL RX (6 MONTHS)**

WEGOVY, SAXENDA

PHENTERMINE

- 12 years or older
- 17 years or older
- Patient age ≥12 years to <18 years must have an initial BMI per CDC growth charts at the 95th percentile or greater for age and sex (obesity); OR
- Patient age ≥12 years to <18 years with BMI in the 85th 94th percentile (overweight) per CDC growth charts and has at least one of the following weight-related coexisting conditions:
 - Diabetes, sleep apnea, hypertension, or dyslipidemia; AND

ZEPBOUND

- 18 years or older
- Initial BMI ≥ than 30 kg/m2; OR
- Initial BMI ≥ than 27 kg/m2 but <30 kg/m2 and at least one of the following:
 - Hypertension, coronary artery disease, diabetes, dyslipidemia, or sleep apnea; OR
 - This medication is being prescribed for cardiovascular risk reduction in members with prior myocardial infarction, prior stroke, or peripheral arterial disease; AND
- 1. Prescriber attests that the patient will not use more than one weight loss medication in this drug class concurrently **AND** Prescriber attests that the patient will not use an anti-obesity GLP-1 agonist (Wegovy, Saxenda or Zepbound) concurrently with a DPP4 inhibitor; **AND**
- 2. For patients with an eating disorder, prescriber attests that treatment has been optimized and confirms the safety and appropriateness of this anti-obesity treatments;
- 3. Prescriber attests that metabolic or other reason(s) for obesity/symptoms have been ruled out or diagnosed and treated (e.g., thyroid dysfunction, diabetes, sleep apnea, etc.): **AND**
- 4. Prescriber attests to patient's absence of any contraindications to use of the requested product, including pregnancy, lactation, a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type II; **AND**
- 5. Prescriber attests medication therapy is part of a total treatment plan including diet and exercise/activity as appropriate for the patient's ability; AND
- 6. Prescriber attests that patient has been informed weight may return with cessation of medication unless healthy lifestyle diet and activity changes, as appropriate for the patient's ability, are permanently adopted.

MDHHS recommends that prescribers consider the benefits of a diabetes prevention program for their patients.

ANTI-OBESITY MEDS for COMMERCIAL



Prior Authorization Details

PLAN: AETNA COMMERCIAL

MEDICATION: Wegovy **POLICY**: #4774-A 08-2022: michmed.org/QRQMm

- 1. 18 years or older AND
 - a. The patient has completed at least 3 months of therapy with the requested drug at a stable maintenance dose, AND
 - b. The patient lost at least 5 percent of baseline body weight OR the patient has continued to maintain their initial 5% weight loss. Documentation is required for approval.

OR

- c. The requested drug will be used with a reduced calorie diet and increased physical activity for chronic weight management in an adult, AND
- d. The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy AND BMI of 30+ OR BMI of 27+ with at least one weight related comorbid condition (e.g. hypertension, type 2 diabetes, dyslipidemia).

PLAN: MICHIGAN BCBSM/BCN COMMERCIAL

IMPACTED PATIENTS: BCBSM/BCN Insured Large Group Commercial Members

MEDICATIONS: All GLP-1 RA's for weight loss - Saxenda, Wegovy, Zepbound

Coverage for GLP-1 weight loss drugs for fully insured large group commercial members ended Jan. 1, 2025. Commercial members with self-funded group benefits may have coverage for GLP-1 weight loss drugs if their employer elected to cover these medications.

Commercial self-funded members with coverage for weight loss GLP-1 must fulfill either the 'Standard' coverage criteria or the 'Teladoc Comprehensive Weight Management' coverage criteria to qualify, depending on which criteria their employer has elected to apply. Please use the link below to view these coverage policies.

POLICY: michmed.org/zRQZB

See also: June 6, 2024 provider alert: michmed.org/Z7eqq

Providers can use OptumRx's real-time prescription benefit check (RTPBC) tool, called PreCheck MyScript, to determine if a particular drug is covered under their patient's pharmacy benefit, and to estimate their patient's out-of-pocket costs for specific drugs. This tool is available at no cost and is accessible online through ereferrals.bcbsm.com/bcbsm/bcbsm-drugs-pharm-benefit.shtml, or may be integrated with the provider's EHR system*

Providers should use electronic prior authorization (ePA) tools such as CoverMyMeds or SureScripts to determine which coverage criteria apply based on their patient's pharmacy benefit. These ePA tools provide coverage insights specific to the patient's benefit design and are available at no cost and are accessible online through the Availity Provider Portal, or may be integrated with the provider's EHR system*

*Integration capabilities for real-time prescription benefit check (RTPBC) and ePA platforms may vary by different EHR systems.

MEDICATION: Contrave, Qsymia

- 1. Age ≥ 18 years old
- 2. BMI \geq 30, or \geq 27 with one weight related condition
- 3. Current weight (within 30 days) must be submitted to the plan for review
- 4. Active participation for a minimum of 6 months in a covered BCBSM/BCN lifestyle modification program OR active participation for a minimum of 6 months in an alternative concurrent lifestyle modification program (e.g. recent food diaries, exercise logs, program receipts, app participation, etc.) if member does not have access to a covered BCBSM/BCN program
- 5. Not to be used in combination with other weight loss products

CGMs for Medicare/Advantage Plans



| Check out Coverage Checker |
|----------------------------|
| Now available online: |
| mct2d.org/coverage-checker |
| |

| | | | | Seed Strong to Many related. | | |
|------------------------------------|---|--------------------------------------|--|--|---|--|
| PLAN | BENEFIT TYPE | TYPE 2 DIABETES DIAGNOSIS <u>AND</u> | | ADDITIONAL DOCUMENTATION | ORDERING | |
| | | INSULIN (| OR NON-INSULIN CRITERIA | DOCUMENTATION | | |
| MEDICARE Part B michmed.org/ dJ8z3 | Order through DME | Insulin treated | "Problematic hypoglycemia" defined as EITHER: Level 2 at least TWO that persist despite at least two prior med adjustments and/or modifications to treatment plan (e.g. raising A1c targets) OR Level 3 history of ONE event ———————————————————————————————————— | Visit for T2D Mgmt: Within 6 months (virtual or in-person) CGM training: Pt or caregiver has received appropriate training. FDA indication for use: For diabetes treatment decisions | DME Preferred Models Abbott Freestyle Libre 2, 2 Plus, 3*, or 3 Plus, Dexcom, and Medtronic *If pt does not have a Libre 2 reader and does not need a standalone reader Note: Abbott Freestyle Libre 2 & 3 will be discontinued 09/30/2025. prescription for 2 Plus or 3 Plus will be needed to avoid gaps in care. | |
| Blue Care Network | Order through Same as Pharmacy Medicare Part | | Same as Medicare Part | PRIOR AUTH: Use CoverMyMeds. See BCBSM Disclaimer on last page of CGM guide. | | |
| (BCN) MA | Pharmacy Billed Under Medical | B | B | Same as Medicare Part B. Patients with non-UAW Trust Group Medicare who are experiencing difficulty obtaining CGM from retail pharmacy under Part B coverage: 800-437-3803 or email Part B mailbox: masrx@bcbsm.com | Pharmacy Preferred Model Abbott Freestyle Libre*, Dexcom *If pt does not have a Libre 2 reader and does not need a standalone reader Note: Abbott Freestyle Libre 2 & 3 will be discontinued 09/30/2025. prescription for 2 Plus or 3 Plus will be needed to avoid gaps in care. | |
| HAP MA | Order through Pharmacy | insum | 3+ non-insulin oral medications | PRIOR AUTH: Needed if no insulin, use CoverMyMeds. | Preferred Models Dexcom G6 or G7, Freestyle Libre 2, 2 Plus, 3, or 3 Plus | |
| | | | AND Uncontrolled A1c | | \$0 copay, see preferred vendor Preferred Vendor Pharmacy Advantage | |

document positive clinical

response (i.e. improved A1C, reduced hypoglycemia)



Check out Coverage Checker Now available online: mct2d.org/coverage-checker

| | | | | | <u> </u> |
|---|-------------------------------|--------------------------------------|---|---|---|
| PLAN | BENEFIT TYPE | TYPE 2 DIABETES DIAGNOSIS <u>AND</u> | | ADDITIONAL | ORDERING |
| PLAN | | INSULIN OF | NON-INSULIN CRITERIA | DOCUMENTATION | ORDERING |
| | | | | PRIOR AUTH: CoverMyMeds or M | DHHS michmed.org/BnJxD. |
| MICHIGAN MEDICAID michmed.org/ Dyeme | Order through DME | Insulin treated | T2D cared for by: PCP, NP, PA, or Endocrinology CGM Education: Patient (or caregiver) has been educated on the use of the CGM and is willing and able to a CGM | Documentation within last 90 days, MUST ALSO HAVE: 1. Frequency of insulin administered per day or IF using insulin pump 2. Current treatment plan. Refill Limitations Year 1 1st order: Written for 6 months. 2nd order: Written for 6 months. Year 2 Orders: Written for 12 months. | Preferred Models Abbott Freestyle Libre 2, 2 Plus, 3*, or 3 Plus; Dexcom G6 or G7 Note This policy applies to Medicaid Fee-for-Service (FFS). MHPs and ICOs must provide the full range of covered services described in this policy at a minimum and may choose to provide services over and above those specified. For beneficiaries enrolled in |
| Medicaid michmed.org/ gRWVY | Pharmacy OR DME | | Treatement with non-insulin | PRIOR AUTH: CoverMyMeds or <u>m</u> | a MHP or ICO, the provider must check with the beneficiary's MHP/ICO for prior authorization requirements ichmed.org/nDqkD. |
| Blue Cross Complete (Medicaid) michmed.org/ PJGPA | Order through Pharmacy OR DME | Insulin treated OR | antihyperglycemic drug ONE of the following (1-8) MUST be documented if NOT on insulin 1. Hypoglycemia (frequent, unaware, OR nocturnal) 2. Weight gain: >5 lb in last 12 months | 4. Need for medication changes 5. Initiation of lower carb diet 6. Unable/reluctant to test finger BG 7. On two or more T2D meds 8. Care Team: Working with pt to improve diet/exercise | Preferred Models: Abbott Freestyle Libre 2, 2 Plus, 3, or 3 Plus; Dexcom G6 or G7 Search pharmacy network bccmi.darwinrx.com/ PharmacyLocator For reauthorization after 12- months: Treatment of T2D without insulin, must |

12 months

3. A1C ≥ 7%

CGMs for Commercial Plans



| | BENEFIT TYPE | TYPE 2 DIABETES DIAGNOSIS <u>AND</u> | | ADDITIONAL | |
|--|--|---|---|--|---|
| PLAN | | INSULIN | OR NON-INSULIN CRITERIA | DOCUMENTATION | ORDERING |
| AETNA Formulary michmed.org/ 97Ay9 | Order through Pharmacy OR DME | Not required | Only "Clinician's recognition of BENEFIT to patient." No T2D Dx required. | | Preferred Devices Dexcom G6/G7 (Pharmacy or Medical), Freestyle Libre (through Medical benefit <i>only</i>) |
| | IF PRESCRI | BER IS A CURRENT MCT | 72D AND PDCM PHYSICIAN MEME | BER: (AS OF JUNE 1, 2024) | |
| BCBSM Consult individual plan MCT2D- specific CGM policy as of 6/1/24: michmed.org/ AnjzA | Order through Pharmacy OR DME To verify pharmacy or DME: Patient should call the number on the back of insurance card or log in to member.bcbsm .com | If pharmacy benefit and prescriber is an MCT2D or PDCM physician: Insulin is Not required Non-MCT2D or PDCM participating prescribers: See next page for BCBSM coverage criteria. | None | Prescribing physician must attest to being a current physician member of MCT2D or PDCM. Include in prescription order. For Pharm RX: No PA required for MCT2D physicians. For DME: PA auto-approved for MCT2D physicians if the PA is reviewed by Northwood, Inc. ² | Pharmacy Preferred Models Abbott Freestyle Libre 2, 2 Plus, 3, or 3 Plus; Dexcom G6, G7¹ Note: Abbott Freestyle Libre 2 & 3 will be discontinued 09/30/2025. prescription for 2 Plus or 3 Plus will be needed to avoid gaps in care. For list of network DME vendors, please visit bcbsm.com/individuals/find-care/. Use the "Find a Doctor" tool to search for network DME suppliers.² |

^{*}Criteria for pregnant patients: "Pregnant individuals that are not on insulin therapy AND who experience postprandial hyperglycemia as defined by ACOG."

BCBSM Disclaimers and Tips

Please see 02/2025 BCBSM FAQ for CGM Prescribing Providers document: ereferrals.bcbsm.com/docs/common/common-cgm-products-faq-for-prescribing-providers.pdf.

*Criteria for pregnant patients: "Pregnant individuals that are not on insulin therapy AND who experience postprandial hyperglycemia as defined by ACOG."

Preferred CGM Devices

[1] At \$0 Copay Tier: Dexcom G6 receiver, Dexcom G6 transmitter, Dexcom G7 receiver. Northwood, Inc. does not manage or distribute the Eversense CGM implantable sensor. Requests for authorization for Eversense are reviewed by BCBSM/BCN and should be submitted via e-referral after verification of member eligibility and benefits.

Prior Authorization: Authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members. Review patient eligibility through the Eligibility & Benefits Inquiry application within the BCBSM provider portal: www.availity.com. Step 1: Access application on the Patient Registration menu at the top of the Availity home screen. Step 2: Use this application to confirm whether the BCBSM/BCN commercial member has Diabetes Supplies covered under their medical (DME) benefit, and to verify whether the member has pharmacy benefit coverage. Procedure codes billed under the medical benefit that require PA approval (including CGM): ereferrals.bcbsm.com/docs/common/common-procedure-codes-that-require-prior-auth.pdf

DME

[2] More info on preferred BCBSM DME vendor Northwood: <u>ereferrals.bcbsm.com/docs/common-northwood-dmepos-faq.pdf</u>. Information on DME coverage under the medical benefit for BCBSM/BCN commercial and Medicare beneficiaries: ereferrals.bcbsm.com/bcn/bcn-dme-po.shtml



Check out Coverage Checker Now available online: mct2d.org/coverage-checker

PLAN

BENEFIT TYPE **TYPE 2 DIABETES DIAGNOSIS AND**

INSULIN

OR NON-INSULIN CRITERIA

ADDITIONAL DOCUMENTATION

ORDERING

IF PRESCRIBER IS NOT A CURRENT MCT2D AND PDCM PHYSICIAN MEMBER:

BCBSM

Consult individual plans

New CGM policy as of 3/1/25 michmed.org/ w8nMW Order through
Pharmacy
OR DME

To verify pharmacy or DME: Patient should call the number on the back of insurance card or log in to member.bcbs m.com

Insulin requiringVerified with

claims lookback within 365 days when processed at the pharmacy

MCT2D and PDCM prescribers: See previous page for CQI-specific coverage criteria "Problematic hypoglycemia" defined as EITHER:

Level 2: At least TWO events with at least tow prior med adjustments and/or modifications to treatement plan (e.g. raising A1C targets)

Level 2 defined as glucose less than 54 mg/dL.

OR

OR

Level 3: At least ONE event

Level 3 defined as less than 54 mg/dL with altered mental state and/ or physical state requiring third party assistance to treat

PRIOR AUTH: For DME/medical benefit, submit via Northwood. For pharmacy benefit, use CoverMyMeds. See below BCBSM disclaimers.

For Pharm RX: Complete ePA (CoverMyMeds)

For DME: Complete prior authorization via DME supplier. PA review from Northwood, Inc. may be required. For more information, please refer to: ereferrals.bcbsm.com/docs/common/common-northwood-dmepos-faq.pdf

Pharmacy Preferred Models

Abbott Freestyle Libre 2, 2 Plus, 3, or 3 Plus; Dexcom G6, G7¹

For list of network DME vendors, please visit bcbsm.com/individuals/findcare/. Use the "Find a Doctor" tool to search for network DME suppliers.²

BCBSM Disclaimers and Tips

Please see 02/2025 BCBSM FAQ for CGM Prescribing Providers document: ereferrals.bcbsm.com/docs/common/common-cgm-products-fag-for-prescribing-providers.pdf.

Preferred CGM Devices

[1] At \$0 Copay Tier: Dexcom G6 receiver, Dexcom G6 transmitter, Dexcom G7 receiver. Northwood, Inc. does not manage or distribute the Eversense CGM implantable sensor. Requests for authorization for Eversense are reviewed by BCBSM/BCN and should be submitted via e-referral after verification of member eligibility and benefits.

Prior Authorization: Authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members. Review patient eligibility through the Eligibility & Benefits Inquiry application within the BCBSM provider portal: www.availity.com.

Step 1: Access application on the Patient Registration menu at the top of the Availity home screen.

Step 2: Use this application to confirm whether the BCBSM/BCN commercial member has Diabetes Supplies covered under their medical (DME) benefit, and to verify whether the member has pharmacy benefit coverage. Procedure codes billed under the medical benefit that require PA approval (including CGM): ereferrals.bcbsm.com/docs/common/common-procedure-codes-that-require-prior-auth.pdf

How to submit pharmacy benefit PA for BCBSM/BCN commercial members: https://ereferrals.bcbsm.com/bcbsm/bcbsm-drugs-pharm-benefit.shtml

DME

[2] More info on preferred BCBSM DME vendor Northwood: <u>ereferrals.bcbsm.com/docs/common/common-northwood-dmepos-faq.pdf</u>. Information on DME coverage under the medical benefit for BCBSM/BCN commercial and Medicare beneficiaries: <u>ereferrals.bcbsm.com/bcn/bcn-dme-po.shtml</u>

^{*}Criteria for pregnant patients: "Pregnant individuals that are not on insulin therapy AND who experience postprandial hyperglycemia as defined by ACOG."

michmed.org/

zRwGW

PREFERRED

DME SUPPLIERS

866-259-1414

COVERAGE GUIDE

CGMs for Commercial Plans



www.byramhealthcare.com/

1-877-902-9726

1-800-321-0591

Check out Coverage Checker Now available online: mct2d.org/coverage-checker

| | BENEFIT TYPE | TYPE 2 DIABETES DIAGNOSIS <u>AND</u> | | ADDITIONAL | |
|--|---|---|--|---|---|
| PLAN | | INSULIN | OR NON-INSULIN CRITERIA | DOCUMENTATION | ORDERING |
| IIAD. | Order through | Insulin | Tried and failed at least | PRIOR AUTH: Needed if no insu | ılin, use CoverMyMeds. |
| HAP (COMMERCIAL) Formulary michmed.org /gdV9P | Pharmacy Tier 0 (Zero Cost) | Verified with claims lookback within 120 days | OR THREE (3) oral diabetes medications in the last 120 days | | Preferred Models Dexcom G6 or G7, Freestyle Libre 2, 2 Plus, 3, or 3 Plus \$0 copay, see preferred vendor |
| | | | | | Preferred Vendor Pharmacy Advantage |
| PRIORITY (TRAD & OPTIMIZED) michmed.org/ yq299 michmed.org/ BA4Kb | Order through Pharmacy | Insulin Verified with RX fill within last 6 months | | | Preferred Models Freestyle Libre 2, 2 Plus, 3, or 3 Plus; Dexcom G6 or G7 |
| UNITED (COMMERCIAL) michmed.org/ nmxYW [1] Note: MCT2D members who are UHC in- network providers can bypass PA and DME. Contact UHC if having prescribing | IF MCT2D¹ Order through Pharmacy | None T2D Dx is the only requirement for patients with OptumRX, when MCT2D. | If not MCT2D: EITHER: • TWO or more Level 2 hypoglycemia events that persist despite multiple attempts to adjust medication(s) or modify diabetes treatment plan • ONE or more Level 3 hypoglycemic event PLUS • 4x daily testing | PRIOR AUTH: If not MCT2D, submit via Optum RX ePA michmed.org/eWmY5 • T2D Dx • Lab results and office notes from within the last three months • Treatment plan • Current signed physician order • Make and model of the device requested | Preferred Models Abbott Freestyle Libre 2, 2 Plus, 3, or 3 Plus; Dexcom G6 or G7 |
| | If not MCT2D, DME or Pharm acy with PA | 3x daily insulin | | | Preferred Vendors See below |
| issues, using the MCT2D Prior Auth Provider Escalation form: | UNITED HEAL CARE (UHC) | TH AdaptHealth LLC https://adapthealt | Advanced Diabetes Supply h.com/ https:// | https:// | dgepark ttp://www.edgepark.com/ |

www.northcoastmed.com

1-866-422-4866

CGM ORDERING: DME or PHARMACY

| | | DME | PHARMACY | NOTES |
|--------------------|---|-------------------------------------|--|--|
| | MEDICARE PART B | • | | TIP: Patient must be on basal insulin to be covered. |
| NTAGE | BCBSM MEDICARE ADVANTAGE | | ⊘ * | *Unless Medicare UAW Trust group, use DME |
| MEDICARE ADVANTAGE | BLUE CARE NETWORK MEDICARE ADVANTAGE | | • | |
| MEDIC | HAP MEDICARE ADVANTAGE | | • | |
| | MICHIGAN MEDICAID | • | | |
| MEDICAID | BLUE CROSS COMPLETE MEDICAID | • | • | Either can be used, no preferred copay. <i>Tip:</i> Less documentation is required for pharmacy. |
| | MOLINA MEDICAID | • | • | |
| | AETNA | | • | |
| COMMERCIAL | BCBSM/BCN | Patients with WEDICAL benefit ONLY | Pts with MEDICAL AND PHARMACY benefit | Check your insurance card or member portal for specific coverage. See instructions below this table. |
| | НАР | | • | |
| | PRIORITY | | • | |
| | UNITED | • | • | Either can be used, no preferred copay. |

Coverage Check for BCBSM/BCN Commercial Patients

Option 1: Check your insurance card: Look for an "RX" symbol and information for an "RXBIN" and/or "RxGRP." If present, send CGM prescription to the **pharmacy**.

Option 2: Log into member.bcbsm.com: Then, click on **'My Coverage.'** Under the "Benefits" heading, look for "**Prescription**." If present, send CGM prescription to the **pharmacy**. If not, send to **DME**.





COVERAGE GUIDE DEFINITIONS AND DISCLAIMERS

PRESCRIBER TIP TO BYPASS PRIOR AUTHORIZATION

Include type 2 diabetes ICD10 code in both the 1.) medical claim for the patient's office visit as well as the 2.) prescription.

For the prescription, look for the "Note to pharmacy" field in Epic (or equivalent field in your EMR). Avoid placing in the "sig" field.

Why? Having T2D diagnosis code in both the prescription and visit claim, can reduce likelihood of PA for some plans. Many insurance plans check coverage requirements using an auto lookback in either medical claims or RX before authorizing coverage.

ICD10 Codes for Type 2 Diabetes

Common list, see full list at www.aapc.com/codes/icd-10-codes/E11

Without Complications: E11.9

Without complications + with insulin: E11.9, Z79.4

With hypoglycemia without coma: **E11.649** With hypoglycemia with coma: **E11.641**

With hyperglycemia: E11.65

With diabetic chronic kidney disease: E11.22

With unspecified diabetic retinopathy: **E11.31**With moderate non proliferative diabetic retinopathy:

With proliferative diabetic retinopathy: E11.35

With diabetic neuropathy, unspecified: E11.40

Prescription code add-on to above ICD10 codes With insulin (Z79.4)

Deductible

Predetermined amount that must be paid annually before insurance pays for anything.

Copayment

Set amount paid for a prescription.

Co-insurance

Amount you pay after your deductible is met. Your insurance pays their portion. Co-insurance only applies to prescriptions and services covered under your health plan.

Medication tier

Levels of insurance medication coverage: You play a smaller amount for a lower tier and a higher amount for a higher tier.

Out-of-pocket max

Annual limit on what you pay before insurance covers 100% of covered services. Deductibles, copayment, and co-insurance all apply toward your out-of-pocket maximum.

Prior authorization

Request made by your health care provider to your insurance company for coverage of a medication.

Quantity limit

Limitation on the amount of medication (# of pills, pens, etc) covered for a period of time.

Step therapy


Medication you must have tried prior to approval of a non-preferred medication, typically prior to trying a more expensive medication.

Pharmacy Carve-Out

Some insurance plans allows for pharmacy carve-outs, where prescription drug coverage is provided by a pharmacy benefits manager (PBM) and may not reflect the same coverage as the medical policy's medication formulary.

Do I have a pharmacy carve-out?

Check your insurance ID card. For example, if you have Priority Health, look for "Optimized RX: Yes" on the back of the card





APPENDIX: FORMULARY, STEP THERAPY, PRIOR AUTHORIZATION, DME POLICY LINKS

| PAYOR | R 2025 FORMULARY ST/PA GUIDELINES CGM POLICY | | PROVIDER PHONE | |
|--------------------------------|--|---|---|-------------------------------------|
| Medicare | See MA plans | See MA plans | michmed.org/dJ8z3 | 800-633-4227 |
| MA: Aetna | michmed.org/8NQrk | michmed.org/KqrMw | See Medicare/CMS policy listed above | 800-624-0756 |
| MA: BCBSM | michmed.org/DymRY | michmed.org/yqVYZ | michmed.org/PYZgY | 800-344-8525 DME: 1-800-447-9599 |
| МА: НАР | michmed.org/WAZqQ | michmed.org/vJV3A | See Medicare/CMS policy listed above | 800-292-2550 |
| MA: Humana | michmed.org/kQ894 | michmed.org/kQkYr GLP: michmed.org/BnNrm | See Medicare/CMS policy listed above | 800-523-0023 |
| MA: Priority | michmed.org/7NVGN | PA: <u>michmed.org/</u> <u>MMxnk</u> ST: <u>michmed.org/QkZxq</u> | See Medicare/CMS policy listed above | 800-942-4765 |
| MA: United | michmed.org/YkDR3 | n/a | See Medicare/CMS policy listed above | 800-711-4555 |
| MA: Wellcare | michmed.org/gRWDV | n/a | See Medicare/CMS policy listed above | 855-538-0454 |
| Aetna | michmed.org/97Ay9 | michmed.org/KqrMw michmed.org/7kXWr michmed.org/QRQMm | michmed.org/3xAqb | PA 800-414-2386 |
| BCBSM | michmed.org/nmxVD | michmed.org/zRQZB | michmed.org/w8nMW | 800-344-8525 DME: 1-800-447-9599 |
| Express Scripts | michmed.org/Dyq2x | michmed.org/3xAey | n/a | 888-327-9791 |
| НАР | michmed.org/qdV9P | Use Provider Portal hap.org/providers/ provider-resources | michmed.org/WXBmd | 888-427-6464 |
| Priority Traditional | michmed.org/yq299 | michmed.org/jm85Q | michmed.org/dJzPq | 800-942-4765 |
| Priority Opimized | michmed.org/BA4Kb | michmed.org/jm85Q | michmed.org/dJzPq | 800-942-4765 |
| United | michmed.org/7NJrY | SGLT2i: michmed.org/Yk9Yb GLP-1 RA: michmed.org/vJmqe | michmed.org/nmxYW | 800-711-4555 |
| Medicaid | michmed.org/N2wn8 | michmed.org/2VP94 | michmed.org/Dyeme | 800-292-2550 |
| Blue Cross Complete | michmed.org/xNX5W | michmed.org/xNX5W | michmed.org/PJGPA | See region specific # |
| McLaren | michmed.org/QRr9A | n/a | n/a | 888-327-0671 |
| Molina | michmed.org/vJ4rz | michmed.org/JDqXY | michmed.org/gRWVY | 855-326-5059 |